What does this article add?
KIM-1/TIM-1 acts as an important gateway to the entry of the virus into
the cell and its increased level of severely ill patients seems to
confirm this. Treatments for this gateway can play an important role in
treatment in COVID-19. In addition, the falling level of suPAR, which
plays a role in body defense and fibrinolisis, with the weight of the
disease may be the cause of parenchymal fibrosis development in
patients, increased predisposition to thromboembolic events and
increased virulence. This issue seems to need to be confirmed through
more extensive research.